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Type 2 diabetes is caused by insulin resistance coupled with an inability to produce enough insulin to control
blood glucose, and thiazolidinediones (TZDs) are the only current antidiabetic agents that function primarily
by increasing insulin sensitivity. However, despite clear benefits in glycemic control, this class of drugs has
recently fallen into disuse due to concerns over side effects and adverse events. Here we review the clinical
data and attempt to balance the benefits and risks of TZD therapy.We also examine potential mechanisms of
action for the beneficial and harmful effects of TZDs, mainly via agonism of the nuclear receptor PPARg.
Based on critical appraisal of both preclinical and clinical studies, we discuss the prospect of harnessing
the insulin sensitizing effects of PPARg for more effective, safe, and potentially personalized treatments of
type 2 diabetes.Type 2 diabetes (T2DM) is characterized by insulin resistance
and b cell failure, and thiazolidinedione drugs (TZDs) are the
only current antidiabetic agents that function primarily by
increasing insulin sensitivity. However, this class of drugs has
recently fallen into disuse due to concerns over side effects
and adverse events. The rise and fall of TZDs is demonstrated
by their use in ambulatory diabetes visits: from 6% in 1997 to
41% in 2005 and down to 16% by 2012 (Turner et al., 2014).
Anecdotal evidence suggests an even steeper decline since
then, as even diabetes specialists now deploy TZDs sparingly,
given the proliferation of other treatment options. With this
decline in clinical use, research publications on TZDs have
also decreased, though not to the same extent (Figure 1), re-
flecting the continuing promise of insulin sensitization to treat
and prevent T2DM and cardiometabolic disease. This review
summarizes the beneficial and adverse effects of TZDs,
focusing on potential mechanisms for each, and highlights
recent clinical, basic, and translational studies from the past
several years that have sent the field into new and unexpected
directions.
TZDs were first reported as insulin-sensitizing drugs in the
early 1980s by the pharmaceutical company Takeda (Fujita
et al., 1983), but their mechanism remained a mystery until
the mid-1990s, when they were found to be ligands for the
nuclear receptor transcription factor PPARg (Lehmann et al.,
1995). PPARg is expressed at high levels in adipose tissue,
where it functions as a master regulator of adipocyte differenti-
ation, and at much lower levels in other tissues (Tontonoz and
Spiegelman, 2008). The simplest model for TZD function in-
volves PPARg agonism in adipose tissue, but recent studies
described below suggest alternatives and additions to this
model.
TZDs Are Potent Insulin Sensitizers which Treat and
Prevent T2DM
Three TZDs have been FDA approved for diabetes: troglita-
zone (Rezulin), rosiglitazone (Avandia), and pioglitazone (Actos)(Figure 2 describes various PPARg agonist drugs that are dis-
cussed in the text). Troglitazone was introduced in 1997 but
withdrawn from the market in 2000 due to increased risk of liver
failure from fulminant hepatitis (Kohlroser et al., 2000). Some
studies suggest the cause is hepatotoxic reactive metabolites
of troglitazone (Yokoi, 2010), while others indicate that troglita-
zone activates the pregnane X receptor in humans, but not
rodents (Jones et al., 2000). Though the exact mechanism is still
uncertain, PPARg activation is not thought to be involved, and
hepatotoxicity is not a TZD class effect but an idiosyncratic
effect of troglitazone. Rosiglitazone and pioglitazone were both
FDA approved in 1999, but pioglitazone has become the TZD
of choice for reasons described below.
TZDs lower hemoglobin A1c potently by 1% as monother-
apy in T2DM, where they notably do not cause hypoglycemia
like insulin or insulin secretagogues (i.e., sulfonylureas), and
they can be used in combination with other antidiabetic agents
(reviewed in Yau et al., 2013). The first-line drug metformin is
often described as an insulin sensitizer, but its primary effect is
suppression of hepatic glucose production, while its effects on
peripheral insulin sensitivity are quite small, variable across
studies, and absent in a meta-analysis (Natali and Ferrannini,
2006). In the same analysis, TZDs have large and consistent
effects improving insulin sensitivity. Furthermore, the ADOPT
randomized controlled trial (RCT) showed that rosiglitazone
provided more durable glycemic control than metformin or a
sulfonylurea (Kahn et al., 2006; Table 1 describes the key clinical
studies that are discussed in the text).
Insulin sensitization also appears to be the mechanism
whereby TZDs prevent or delay development of T2DM in
individuals with prediabetes. The ACT NOW RCT involved 602
patients with impaired glucose tolerance (IGT), and pioglitazone
decreased progression to T2DM by 74% over 2.4 years
(DeFronzo et al., 2011). Earlier studies of patients with prediabe-
tes showed that troglitazone (Knowler et al., 2005) or rosiglita-
zone (Gerstein et al., 2006) similarly decreased progression to
diabetes.Cell Metabolism 20, October 7, 2014 ª2014 Elsevier Inc. 573
Figure 1. The History of TZDs
The graph shows the annual number of TZD-
related publications, with boxes indicating key
events in the rise and fall of this drug class. For
2014, publications through May were adjusted to
a full year.
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Nonalcoholic fatty liver disease (NAFLD) is now the most com-
mon chronic liver disease in the U.S., associated with obesity,
insulin resistance, dyslipidemia, and hypertension, as part of
the metabolic syndrome (Lomonaco et al., 2013). The mildest
form of NAFLD is simple hepatic steatosis, which can progress
to nonalcoholic steatohepatitis (NASH), leading to cirrhosis and
hepatocellular carcinoma. Metformin acts primarily in liver, yet
shows no benefit in NASH (Chalasani et al., 2012). Dysfunctional
adipose tissue plays a key role in NAFLD (Lomonaco et al., 2012),
so targeting adipose tissue with TZDs is an attractive treatment
option. In a small RCT of 55 patients with IGT or T2DM and
NASH, pioglitazone was quite effective at decreasing histologi-
cal liver fat, inflammation, and fibrosis (Belfort et al., 2006). The
subsequent PIVENS RCT with 247 nondiabetic patients showed
that pioglitazone improved all secondary NASH endpoints
(Sanyal et al., 2010). Excellent reviews of NAFLD have been pub-
lished recently (Lomonaco et al., 2013), and current practice
guidelines endorse the use of pioglitazone for biopsy proven
NASH (Chalasani et al., 2012). Notably, based on the FLIRT trial,
rosiglitazone does not appear as effective as pioglitazone in
NASH (Ratziu et al., 2010), and gene expression changes in liver
biopsies from this trial even suggested proinflammatory changes
(Lemoine et al., 2013).
In women with polycystic ovarian syndrome (PCOS), guide-
lines recommend metformin or TZDs to decrease androgen
levels, enhance ovulation, and improve glucose tolerance,
though not for first line use in treating hirsutism or infertility
(ACOG Committee on Practice Bulletins Gynecology, 2009). In
practice, metformin is commonly used in PCOS while pioglita-
zone is used sparingly, most likely due to concerns over the
side effects of pioglitazone and metformin’s established safety
in pregnancy.
Fluid Retention, Edema, and Congestive Heart Failure
Due to TZDs
Water retention due to TZDs was noted early, with about 5%
of patients developing peripheral lower extremity edema on
TZD monotherapy and even more in combination with other574 Cell Metabolism 20, October 7, 2014 ª2014 Elsevier Inc.drugs—up to 18% when combined with
insulin (Nesto et al., 2004). Excess fluid
can also lead to exacerbations of
congestive heart failure (CHF); thus
TZDs are contraindicated in patients
with symptomatic heart failure (New
York Heart Association class III or IV).
While TZDs clearly increase CHF events,
these are normally responsive to diuretic
therapy, and TZDs do not appear to in-
crease mortality from CHF (Lago et al.,
2007).Even without clinical signs of edema or heart failure, TZD-
treated patients retain water, typically evidenced by hemodilu-
tion. Even this is controversial, as some methods to assess total
body water indicate hemodilution actually does not account for
the decreased hematocrit on pioglitazone (Berria et al., 2007).
Nonetheless, mouse models show that the apparent volume
expansion requires PPARg expression in the renal collecting
duct (Guan et al., 2005; Zhang et al., 2005), and may involve
the epithelial sodium transporter as well as other pathways in
the renal tubule (reviewed in Be1towski et al., 2013). Regarding
CHF, direct effects of TZDs on cardiac muscle are possible, as
mouse models with either cardiomyocyte-selective overexpres-
sion (Son et al., 2007) or deletion (Duan et al., 2005) of PPARg
have both reported cardiac dysfunction. The cardiotoxic effects
of high doses of rosiglitazone were recently shown to be largely
PPARg independent and involve mitochondrial dysfunction (He
et al., 2014). In human studies, TZDs are associated with lipid
accumulation in cardiomyocytes (Marfella et al., 2009), but pio-
glitazone showed no effect or even beneficial effects on echo-
cardiographic measures of cardiac function (Horio et al., 2005;
Sambanis et al., 2008). TZDs are not generally thought to cause
cardiomyopathy directly, but rather to exacerbate heart failure
via fluid retention in susceptible patients. Recently, some but
not all studies have shown an association between TZD use
and diabetic macular edema (Idris et al., 2012). The mechanisms
for this association may involve the systemic effects of overall
volume expansion as well as local effects in the retina.
Weight Gain on TZDs: Both Fluid Retention and Adipose
Tissue
Many studies of TZDs show a typical reported weight gain of
5 kg over 3–5 years. While there is potential for added weight
due to fluid retention, there is clearly also expansion of adipose
tissue. Studies differ as to the relative contribution of fluid versus
adipose tissue: even on the same 45 mg dose of pioglitazone,
some measure 75% of the added weight due to water retention
(Basu et al., 2006), while others propose 89% due to adipose tis-
sue mass (Berria et al., 2007). Multiple imaging studies consis-
tently show a greater increase in peripheral subcutaneous than
Figure 2. PPARg Agonist Drugs
TZDs like pioglitazone and rosiglitazone are potent
PPARg agonists (red), but other weaker or partial
agonists share the TZD structure with different
side chains (blue). There are additional structurally
diverse non-TZD PPARg agoinsts (green and
purple), including dual agonists of PPARa and
PPARg (orange). See text for details.
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even found a decrease in visceral fat (Punthakee et al., 2014).
Rather than an unwanted effect, this adipose tissue weight
gain may be integral to the mechanism of action of TZDs (see
below). Indeed, a positive correlation has been reported be-
tween the degree of weight gain on rosiglitazone and the
improvement in insulin sensitivity (Miyazaki et al., 2005), and be-
tween weight gain on pioglitazone and improved cardiovascular
outcomes (Doehner et al., 2012).
Cardiovascular Disease: Different Effects of
Rosiglitazone and Pioglitazone?
Awidely citedmeta-analysis in 2007 raised concerns that rosigli-
tazone was associated with a significant 43% increased risk of
myocardial infarction (MI), with a 64% increase in cardiovascular
mortality that did not reach statistical significance (p = 0.06) (Nis-
sen and Wolski, 2007). Increased MI risk was surprising, givenCell Metabolism 20mouse models showing that rosiglitazone
markedly inhibits atherosclerosis (Li et al.,
2000). Subsequent meta-analyses also
showed increasedMI risk, thoughwithout
increased mortality (Nissen and Wolski,
2010; Singh et al., 2007). Based on such
studies, in 2010 the FDA placed restric-
tions on rosiglitazone through its risk eval-
uation and mitigation strategies (REMS)
program, requiring patient registration
and special pharmacies. Only one RCT,
an open-label noninferiority study called
RECORD, was specifically designed to
assess cardiovascular outcomes on rosi-
glitazone compared to metformin and a
sulfonylurea. The interim results were
published early in 2007 (Home et al.,
2007) and the final results in 2009
(Home et al., 2009), and these were read-
judicated by independent investigators at
the FDA’s request in 2013 (Mahaffey
et al., 2013). None of these analyses
showed any increased risk of heart attack
or death.
Despite RECORD enrolling 4,447 pa-
tients, the authors note that it was still
underpowered, as a 60% risk or
20% benefit of rosiglitazone could not
be excluded. Nonetheless, given this
new information, in November 2013 the
FDA followed advice of an expert panel
and removed restrictions on rosiglitazone
(FDA, 2013). This decision was supportedby a post hoc analysis of the BARI 2D trial, in which 992 subjects
on rosiglitazone had no significant change in MI with a trend
toward benefit, along with decreased risk of stroke or the com-
posite cardiovascular endpoint (Bach et al., 2013). Furthermore,
a recent reassessment of the observational data linking rosiglita-
zone and MI found many deficiencies and potential for con-
founding (Rawson, 2014). After the storm of controversy and
bad press, it is unlikely this rosiglitazone will ever be widely
used again, as there is no unique benefit for this drug compared
to pioglitazone—except perhaps for bladder cancer risk (see
below). Furthermore, a similar meta-analysis for pioglitazone
showed no excess cardiovascular mortality, and in fact an
18% decrease in cardiovascular endpoints (Lincoff et al.,
2007). An large observational cohort of U.S. Medicare patients
showed that rosiglitazone has cardiovascular harm compared
to pioglitazone (Graham et al., 2010), while a UK cohort study
showed that pioglitazone but not rosiglitazone reduced all-cause, October 7, 2014 ª2014 Elsevier Inc. 575
Table 1. Selected Key Clinical Studies of TZDs and Related Drugs
Trial/Publication Type Design Details Outcome Result Comment
ADOPT: A Diabetes
Outcome Progression
Trial (Kahn et al., 2006)
RCT Patients with newly
diagnosed T2DM
randomized to rosiglitazone,
metformin, or glyburide
4,360 patients, median
4 years
Time to monotherapy
failure
Only 15% failure at 5
years for rosiglitazone,
lower than 21% for
metformin and 34% for
glyburide
Supports notion that
reducing insulin resistance is
beneficial in diabetes
pathophysiology
ACT NOW: Actos Now
for the prevention of
diabetes (DeFronzo et al.,
2011)
RCT Patients with prediabetes
randomized to pioglitazone
or placebo
602 patients, median
2.4 years
Conversion to diabetes Pioglitazone decreased
conversion to diabetes
by 72%
Similar studies previously
showed diabetes prevention
by troglitazone and
rosiglitazone
PIVENS: PIoglitazone or
Vitamin E for Nonalcoholic
Steatohepatitis (NASH)
(Sanyal et al., 2010)
RCT Patients with NASH and
without diabetes randomized
to pioglitazone, vitamin E, or
placebo
247 patients, 96 weeks
of treatment
Improvement in
histologic features of
NASH
Vitamin E, but not
pioglitazone, significantly
improved primary
histological composite
endpoint
Pioglitazone improved all
secondary endpoints: liver
fat, inflammation, and serum
aminotransferase levels
Nissen and Wolski, 2007 meta-
analysis
Data combined by fixed
effects model
42 studies met inclusion
criteria
MI or cardiovascular
death
Rosiglitazone’s odds
ratio for MI 1.43 (1.03 to
1.98; p = 0.03), for
death 1.64 (0.98 to 2.74;
p = 0.06)
Despite many subsequent
studies, the association
between rosiglitazone and
MI remains controversial
(see text for details)
RECORD: Rosiglitazone
Evaluated for Cardiac
Outcomes and Regulation
of glycaemia in Diabetes
(Home et al., 2007)
RCT Patients with T2DM on
metformin or sulfonylurea
monotherapy randomized to
addition of rosiglitazone
4,447 patients, mean
5.5 years
Cardiovascular
hospitalization or death
No significant increase in
cardiovascular mortality
with rosiglitazone
Readjudicated results
(Mahaffey et al., 2013)
support original conclusions,
though study was likely
underpowered
BARI 2D: Bypass Angioplasty
Revascularization
Investigation in Type 2
Diabetes (Bach et al., 2013)
post-hoc
analysis
In original RCT, patients with
T2DM and stable coronary
disease were randomized to
several interventions
992 on rosiglitazone,
mean 4.5 years
Mortality, MI, stroke No increase in MI on
rosiglitazone, with
significant decrease in
composite endpoint
Agrees with RECORD,
though trial not originally
designed to study effects of
rosiglitazone
TIDE: Thiazolidinedione
Intervention with vitamin D
Evaluation (Punthakee et al.,
2012)
RCT Patients with T2DM
randomized to rosiglitazone,
pioglitazone, vitamin D, or
placebo
2,553 patients, mean
162 days
MI, stroke, or
cardiovascular death
Study initially required by
FDA but terminated in
2013 when deemed no
longer feasible or
necessary
Would have been the only
trial comparing rosiglitazone
and pioglitazone head to
head
CHICAGO: Carotid Intima-
Media Thickness (CIMT) in
Atherosclerosis using
Pioglitazone (Mazzone et al.,
2006)
RCT Patients with T2DM
randomized to pioglitazone
or glimepiride
462 patients, mean
7.7 years
Change from baseline
in CIMT
Pioglitazone slowed
progression of CIMT
compared to glimepiride
Evidence that pioglitazone is
beneficial in atherosclerosis,
slowing plaque progression
(Continued on next page)
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Table 1. Continued
Trial/Publication Type Design Details Outcome Result Comment
PERISCOPE: Pioglitazone
Effect on Regression of
Intravascular Sonographic
Coronary Obstruction
Prospective Evaluation
(Nissen
et al., 2008)
RCT Patients with coronary
disease and T2DM
randomized to pioglitazone
or glimeperide
543 patients, duration
18 months
Change from baseline in
atheroma
Coronary atheroma
volume decreased on
pioglitazone, but
progressively increased
on glimeperide
Evidence that pioglitazone is
beneficial in atherosclerosis,
even causing plaque
regression
PROactive: PROspective
pioglitAzone Clinical Trial In
macroVascular Events
(Dormandy et al., 2005)
RCT Patients with T2DM and
evidence of macrovascular
disease randomized to
pioglitazone or placebo
5,238 patients, mean
2.9 years
Composite of mortality,
MI, stroke, and leg artery
revascularization or
amputation
Pioglitazone did not
affect primary composite
endpoint (10%, p =
0.09) but reduced
predefined secondary
endpoint (mortality, MI,
and stroke; 16%,
p = 0.03)
Pioglitazone is effective in
secondary prevention of
cardiovascular disease;
follow-up analyses showed
even more impressive
effects in subgroups with
prior MI or stroke
Colhoun et al., 2012 database
cohort
Scottish national database
of prescriptions,
hospitalizations, and deaths
37,479 patients exposed
to TZD
Hospitalization for hip
fracture
Pioglitazone and
rosiglitazone increased
risk of hip fracture by
15%–20% in men and
women
Prior studies had shown
mainly an association of
TZDs with distal extremity
fractures in women
Neumann et al., 2012 database
cohort
French national databases 155,535 patients
exposed to pioglitazone
Incident cases of bladder
cancer
Pioglitazone significantly
increased bladder
cancer by 22%, with
dose- and duration-
dependent effects
Other studies support a small
but significant increase in
bladder cancer on
pioglitazone, but not
rosiglitazone
Colmers et al., 2012b meta-
analysis
4 RCTs, 7 cohort studies,
and 9 nested case control
studies were pooled
data on 2.5 million
patients
Incidence of cancers at
various sites
TZDs confer a small
(5%–10%) but significant
decreased risk of lung,
colorectal, and breast
cancers
Compared to bladder
cancer, cancers that TZDs
may prevent are more
common and have greater
morbidity and mortality
AleCardio: a study with
Aleglitazar in patients with a
recent acute Coronary
syndrome and type 2 diabetes
mellitus (Lincoff et al., 2014)
RCT Patients with T2DM and
hospitalized with acute
coronary syndrome were
randomized to aleglitazar
versus placebo
7,226 patients, stopped
early after median 2 years
Recurrent heart attack,
stroke, or cardiovascular
death
Aleglitazar did not affect
the primary endopoint
despite having the
expected effects on
lipids and glucose
This trial was stopped early
due to futility, as this dual
PPAR agonist showed no
benefit and the suggestion of
serious adverse events
Fourteen key clinical studies are summarized, in the order they are presented in the text. RCT, randomized controlled trial.
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Reviewmortality relative to metformin (Tzoulaki et al., 2009). Based on
such findings, pioglitazone essentially became the TZD of
choice, and prescribing data from the U.S. and UK clearly
show a switch from rosiglitazone to pioglitazone between 2007
and 2009 (Hampp et al., 2014; Leal et al., 2013). A large FDA-
required RCT called TIDE was designed to compare rosiglita-
zone and pioglitazone head to head for cardiovascular endpoints
(Punthakee et al., 2012), but it has been terminated, as the FDA
deemed it no longer feasible or necessary after the readjudica-
tion of RECORD.
The potential difference in MI risk between pioglitazone and
rosiglitazone may lie in their distinct effects on lipoproteins,
with pioglitazone showing a more favorable effect (triglycerides
decrease 15%, HDL cholesterol increase 10%, with no
effect on LDL or total cholesterol) than rosiglitazone (no effect
on triglycerides, HDL cholesterol increase 10%, but 5%–
10% increases in LDL and total cholesterol) (Chiquette et al.,
2004). This difference in lipid effects may reflect weak PPARa
agonism by pioglitazone (Sakamoto et al., 2000). Subsequent
RCT data validated the favorable effects of pioglitazone versus
rosiglitazone on lipoprotein particle concentration and size
(Deeg et al., 2007). These and other markers of cardiovascular
risk favor pioglitazone, and two studies directly measuring
atherosclerotic plaques in patients with T2DM showed benefits
of pioglitazone compared to the sulfonylurea glimepiride. In the
CHICAGO study, pioglitazone slowed progression of carotid
intima media thickness (CIMT) (Mazzone et al., 2006), while in
PERISCOPE pioglitazone actually led to regression in coronary
atheroma volume assessed by intravascular ultrasound (Nissen
et al., 2008). In the ACT NOW study of patients with prediabetes,
pioglitazone likewise decreased progression of CIMT, and this
was interestingly independent of effects on glycemia, insulin
resistance, lipids, or inflammatory markers (Saremi et al.,
2013). Direct beneficial effects of pioglitazone in the vascular
wall are proposed, and many basic studies have explored
effects of TZDs and PPARg in vascular smooth muscle cells,
macrophages, and endothelial cells (Tontonoz and Spiegelman,
2008).
PROactive was a landmark RCT assessing the effect of pio-
glitazone on secondary prevention of cardiovascular disease in
patients with diabetes, enrolling 5,238 patients for an average
of 2.85 years (Dormandy et al., 2005). While pioglitazone
resulted in a nonsignificant 10% reduction in the primary
composite endpoint (all-cause mortality, nonfatal MI, acute
coronary syndrome, stroke, revascularization of coronary or
leg arteries, and amputation above the ankle), there was a sig-
nificant 16% reduction in the main prespecified secondary
composite endpoint (all-cause mortality, nonfatal MI, and
stroke). In effect, pioglitazone reduced all cardiovascular
endpoints except for peripheral vascular revascularization.
Posthoc subgroup analyses showed that those 2,445 patients
with previous MI had a significant 28% decrease in recurrent
MI on pioglitazone (Erdmann et al., 2007), while those 984
patients with previous strokes had a significant 47% reduction
in recurrent stroke (Wilcox et al., 2007). Despite these impres-
sive cardiovascular benefits to pioglitazone, its use has also
declined markedly, potentially due to ‘‘guilt by association’’
with rosiglitazone and the description of new risks for fractures
and bladder cancer.578 Cell Metabolism 20, October 7, 2014 ª2014 Elsevier Inc.TZDs and Skeletal Fractures
The first large RCT to suggest this association was ADOPT, in
which pre- and postmenopausal women (but not men) random-
ized to rosiglitazone had significantly more fractures (2.74 per
100 patient years) than those receiving metformin or glyburide
(1.54 or 1.29 per 100 patient years) (Kahn et al., 2008). Interest-
ingly, the fractures were not at typical osteoporotic sites of spine
and hip but instead distal fractures of the upper and lower ex-
tremities. RCTs of pioglitazone have showed similar risk, and
multiple observational studies of both rosiglitazone and pioglita-
zone have shown heterogeneity but generally supported this
association with distal fractures in women but not men (reviewed
in Yau et al., 2013). These findings have led to recommendations
against using TZDs in those at risk for osteoporosis and fracture,
such as postmenopausal women. These concerns were ampli-
fied after a recent national database cohort study in Scotland
showed in a large population that risk of hip fracture increased
in both women and men, risk was cumulative (increased by
18% for each year of TZD exposure), and the 90-day mortality
from hip fractures was expectedly high at 15% with or without
TZD (Colhoun et al., 2012). Consistent with this risk, pioglitazone
reduces bone mineral density and content in multiple sites in
men and women (Bray et al., 2013). Of the potential adverse
effects of TZD, fracture risk may be the most convincing reason
to curtail long-term TZD use for treatment and prevention of
T2DM, particularly if increased hip fractures are validated.
Themechanism for the skeletal effects of TZDs remains uncer-
tain. Onemodel involves PPARg activation drivingmesenchymal
precursor cells to adipogenesis rather than osteogenesis, and a
recent translational study with human cells from bone marrow
biopsies supported aspects of this model (Beck et al., 2013).
Also consistent with this model, some mice develop more
bone marrow fat on rosiglitazone, though this effect was not
observed in humans (Harsløf et al., 2011). The molecular mech-
anisms for TZD effects on bone are complex and involve both
decreased osteoblast function and increased osteoclast func-
tion (Grey, 2009). For instance, rosiglitazone was very recently
shown to alter expression in cell culture of a novel micro-RNA
involved in osteoclastogenesis (Krzeszinski et al., 2014), and to
increase the number of circulating osteoclast precursors in post-
menopausal women (Rubin et al., 2014). Studies of TZD skeletal
effects are also complicated by the effects of diabetes itself on
bone, as patients with diabetes have a higher risk of fracture in-
dependent of bone density, and poor glycemic control may itself
worsen fracture risk (Oei et al., 2013).
Pioglitazone and Bladder Cancer
In pharmacological carcinogenicity studies, pioglitazone in-
creased urothelial bladder cancer in male rats, but not in
female rats or mice (reviewed in Tseng and Tseng, 2012), leading
to several studies in humans indicating that pioglitazone in-
creases bladder cancer risk. Adverse event reporting to the
FDA first suggested the risk in 2011 (Piccinni et al., 2011). A
longitudinal cohort from Kaiser Permanente Northern California
(KPNC) of 200,000 diabetic patients with 30,000 on pio-
glitazone showed a nonsignificant 20% increased risk of
bladder cancer overall, but a significant 20% increase in the
subgroup with >24 months of drug exposure (Lewis et al.,
2011). A French retrospective cohort study of 1.5 million
Cell Metabolism
Reviewpatients with 150,000 exposed to pioglitazone used similar
methods to reach similar conclusions: overall pioglitazone signif-
icantly but slightly increased risk by 22%, with dose- and dura-
tion-dependent further increases up to 75% with cumulative
exposure to >28,000 mg (Neumann et al., 2012). Bladder cancer
overall was eight times more common in men in this study, and
consequently it was underpowered to find effects in women.
Nonetheless, all of the excess risk of pioglitazone was in males,
and a lack of effect in females would mirror the apparent sex
selectivity in rats. Analysis of UK general practice databases
confirmed increased bladder cancer risk on pioglitazone (Azou-
lay et al., 2012), though similar population cohorts in Taiwan,
Japan, and Korea failed to show this association (reviewed in
Yau et al., 2013). Two meta-analyses have included these
studies and others to find risk increases of 22%–23%, though
both perform detailed assessments and find moderate overall
risk of bias (Colmers et al., 2012a; Ferwana et al., 2013). Recent
efforts have tried to identify and eliminate potential confounding
sources of bias in these observational studies (Lewis et al.,
2014).
RCTs would be the gold standard to show increased bladder
cancer risk, but the relative rarity of bladder cancer has limited
these efforts. The PROactive study in 2005 initially reported 14
bladder tumors with pioglitazone versus 6 with placebo (p =
0.069), but subsequent elimination of a benign bladder mass
from the placebo group gave significant risk at p = 0.04 (Hill-
aire-Buys et al., 2011). However, the recently published 6 year
interim analysis showed that this imbalance was likely due to
chance, as it did not persist into the follow-up period despite ran-
domized exposure to high cumulative doses of pioglitazone and
the long latency to development of bladder cancer (Erdmann
et al., 2014).
Rat studies have attempted to elucidate pioglitazone’s mech-
anism of bladder carcinogenesis. In addition to pioglitazone, a
number of dual PPARg/PPARa agonists (see below) have also
shown bladder carcinogenicity in rats (Tseng and Tseng,
2012). Some studies support a ‘‘crystalluria hypothesis’’ with
rat-specific formation of urinary solids leading to mucosal irrita-
tion and tumors, which is theorized not to occur in mice and
humans (Sato et al., 2011; Suzuki et al., 2010). However, other
mechanisms are possible, and PPARg-dependent effects have
not been ruled out.
Overall, the weight of current evidence supports a small but
real increase in bladder cancer risk with pioglitazone therapy
(Faillie et al., 2013), while no study has seen increased risk with
rosiglitazone. It is important to note that the absolute risk in-
crease is very small. The French cohort showed that pioglitazone
is associated with an increase from 42.8 to 49.4 cases of bladder
cancer per 100,000 person years (Neumann et al., 2012), mean-
ing an individual’s annual risk goes from 0.043% to 0.049%, or a
0.006% increase in absolute risk. Similarly, a number needed to
harm calculation showed that over 20,000 patients would need
to be treated with pioglitazone to cause one additional case of
bladder cancer (Ferwana et al., 2013).
TZD Effects on Other Cancers
Despite the attention to bladder cancer, the effects of TZDs on
other cancers remain uncertain, and if anything there may be
protective effects. In a population of almost 90,000 veteranswith diabetes, TZD use had no significant effect on prostate
and colon cancer, but there was a significant 33% decrease in
lung cancer (Govindarajan et al., 2007), consistent with pioglita-
zone’s protective effect in amousemodel of lung cancer (Li et al.,
2012). In the study populations that showed increased bladder
cancer risk, the KPNC cohort showed no significant effects of
pioglitazone on the ten most common cancers (Ferrara et al.,
2011), but in the French cohort pioglitazone and rosiglitazone
actually had significant protective effects for several other can-
cers (breast, colon, lung, and head and neck) (Neumann et al.,
2012).
While many individual cohorts showed a neutral effect of TZDs
on cancers (for example, Koro et al., 2007), the largest meta-
analysis to date with data on 2.5 million people supports the
idea that TZDs confer a small (5%–10%) but significant
decreased risk of lung, colorectal, and breast cancers (Colmers
et al., 2012b). Given that these cancers are far more common
than bladder cancer, these decreased risks assuage the
increased risk of bladder cancer. This risk balancing may be
particularly relevant, as the great majority of bladder cancers
on pioglitazone were non-muscle invasive and managed with
transurethral resection (Ferwana et al., 2013), while TZDs could
protect against more common cancers with greater morbidity
and mortality. There are many proposed mechanisms for the
effects of PPARg and TZDs in various cancers, many involving
increased apoptosis, and this extensive literature with much
conflicting data has been reviewed recently (Robbins and Nie,
2012).
Balancing Pioglitazone Clinical Risks and Benefits
The relative risks and benefits of pioglitazone can be inferred
based on the abundance of trial data summarized above and
published mortality statistics in the U.S. (Figure 3) (CDC, 2010;
National Program of Cancer Registries United States Cancer
Statistics [USCS], 2006–2010; Yoon and Yi, 2012). Heart dis-
ease, stroke, and diabetes are the first, fourth, and seventh lead-
ing causes of death, and based on the PROactive trial and
improved glycemic control, pioglitazone might decrease these
deaths by 20%—thus 52 fewer deaths per 100,000. Assuming
that one-third of cirrhosis and liver cancer (9.4 and 5.6 deaths per
100,000) is attributable to NAFLD, and that pioglitazone might
decrease these by 20%, this means another 1 fewer death
per 100,000. This number alone is enough to mitigate the
increased risk of bladder cancer: 4.4 deaths per 100,000
increased by20% is only 0.9 additional deaths. Given that pio-
glitazone may protect 10% against more common cancers,
this means 9 fewer deaths, so pioglitazone would prevent
almost 10-fold more cancer deaths than it causes. Hip fracture
mortality is more complicated. Based on a landmark analysis
of Medicare data, the incidence of hip fractures is 957 and 414
per 100,000 in women and women over 65, with respective 1
year mortalities of 22% and 32% (Brauer et al., 2009), thus an
average mortality of 172 per 100,000. If pioglitazone truly in-
creases hip fractures by 20%, then there are 34 additional
deaths per 100,000 people over 65—similar to the estimate of
21 by Colhoun et al. Thus, fractures due to pioglitazone carry a
much greater mortality than bladder cancer. Considering all
the numbers above, pioglitazone would prevent 60 deaths
and cause only 30 per 100,000, favoring benefits over risksCell Metabolism 20, October 7, 2014 ª2014 Elsevier Inc. 579
Figure 3. Weighing Mortality Risks and
Benefits of Pioglitazone
Age-adjusted mortality rates for the entire U.S.
population were derived from published govern-
ment statistics for 2010-2011. Potential effects of
pioglitazone on mortality from cardiometabolic
causes or certain cancers were approximated
from published analyses. The mortality from hip
fracture is more complex to estimate, as it is not a
proximal cause of death but clearly carries mor-
tality risk in the elderly. See text for details.
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(i.e., the mortality statistics are from the overall population, not
those with T2DM), but they are nonetheless informative.
Basic Science: How Do TZDs Improve Insulin
Sensitivity?
PPARg is the master regulator of adipose tissue development
and function (Tontonoz and Spiegelman, 2008) and is more
abundant in adipocytes than in any other cell type (Chawla
et al., 1994; Tontonoz et al., 1994). Indeed, TZDs have important
effects on adipose biology. TZDs stimulate progenitor stem cells
to differentiate in adipocytes (Tang et al., 2011), and they also
affect mature adipocytes. The ‘‘lipid steal’’ model proposes
that adipose tissue is the metabolically safe place to store fat
(Kim et al., 2003; Ye et al., 2004). In obesity, adipocytes become
overwhelmed and dysfunctional, resulting in elevated serum free
fatty acids and ectopic lipid deposition in liver and muscle, lead-
ing to insulin resistance (Samuel et al., 2010). In this model, TZDs
improve the function of fat to safely store lipid, resulting in
decreased serum free fatty acids, decreased ectopic lipids,
and less insulin resistance. While not fully proven, this model ex-
plains two otherwise paradoxical observations relating obesity
to insulin resistance: (1) TZDs improve insulin sensitivity despite
causing weight gain, and (2) lack of adequate fat (lipodystrophy)
causes extreme insulin resistance (Fiorenza et al., 2011). TZDs
are also effective in treating some patients with partial lipodys-
trophy, including HIV-infected individuals (Hadigan et al., 2004).580 Cell Metabolism 20, October 7, 2014 ª2014 Elsevier Inc.Since TZDs affect transcriptional activ-
ity of PPARg, their mechanisms may be
elucidated by identifying in an unbiased
manner: (1) the transcriptional changes
induced by TZDs or (2) the genomic bind-
ing sites for PPARg. Multiple microarray
analyses of TZD-regulated gene expres-
sion have been performed in cells and
animals, and these have revealed many
candidate genes involved in lipid and
glucosemetabolism. The genes activated
by TZDs are largely consistent with
increased lipid storage capacity in adipo-
cytes but do not truly explain their effi-
cacy (Moore, 2005). With the recognition
of brown-like adipocytes in white adi-
pose tissue (‘‘beige cells’’), it has become
clear that TZDs increase this signature
of browning (Vernochet et al., 2009),
perhaps by a mechanisms involving thebrown fat transcription factor PRDM16 (Ohno et al., 2012; Qiang
et al., 2012), and thus TZDs may also increase fatty acid oxida-
tion and energy expenditure in fat.
Recent advances in DNA sequencing technology have
allowed more detailed probing of TZD effects. Chromatin
immunoprecipitation followed by massively parallel sequencing
(ChIP-seq) has revealed tens of thousands of binding sites for
PPARg throughout the genome, with enrichment near the ex-
pected adipocyte metabolic genes (reviewed in Lefterova
et al., 2014). In cultured mouse adipocytes, TZD treatment did
not induce new PPARg binding sites and had only small effects
on increasing PPARg occupancy at pre-existing sites (Haakons-
son et al., 2013). However, TZDs do have genome-wide effects
increasing recruitment of coactivators to PPARg sites (Haakons-
son et al., 2013; Step et al., 2014), thus providing a mechanism
for TZD gene activation. Notably, TZD treatment results in
repression of similar numbers of genes as are activated, and
the mechanism of nuclear receptor ligand-mediated repression
is unknown. However, a recent analysis of TZD-repressed tran-
scription at enhancers (eRNAs) has shown that these sites lack
PPARg, such that redistribution of coactivators from these sites
to those with strong PPARg binding may account for repression
(Step et al., 2014).
Some targets affected by TZDs and PPARg are hormones
or cytokines secreted by adipose tissue (adipokines), which
communicate with other tissues to affect whole-body meta-
bolism (Halberg et al., 2008). Serum adiponectin levels correlate
Cell Metabolism
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and Rothenbacher, 2008). Clinically, in the ACT NOW study, in-
creases in adiponectin levels correlated with improved insulin
sensitivity on pioglitazone (Tripathy et al., 2014). Consistent
with a causal role of adiponectin in TZD effects, mice lacking
adiponectin show decreased response to TZD but still improve
insulin sensitivity (Nawrocki et al., 2006). Conversely, TZD treat-
ment may decrease levels of other adipose-derived signaling
molecules which are linked to insulin resistance, such as
TNF-a, RBP4, and resistin (reviewed in Ahmadian et al., 2013).
Recent reports have also implicated two other secreted pro-
teins in the fibroblast growth factor (FGF) family in PPARg and
TZD effects, though acting locally in fat rather than as hormones.
TZDs increase adipose tissue expression of FGF21, which acts
in an autocrine or paracrine manner to increase PPARg tran-
scriptional activity (via suppression of Lys107 SUMOylation,
see below), such that diet-induced obese mice lacking FGF21
showed decreased response to TZDs in insulin sensitization,
weight gain, and even fluid retention (Dutchak et al., 2012). How-
ever, another report found that FGF21 null mice responded
normally to TZDs (Adams et al., 2013), so further study will be
necessary to resolve this discrepancy. FGF21 may also mediate
TZD effects on bone, as FGF21 gain of function decreases bone
mass like TZDs, and FGF21 loss of function actually prevents
bone loss due to rosiglitazone (Wei et al., 2012). TZDs also in-
crease expression of FGF1 via PPARg activation, and mice lack-
ing FGF1 show insulin resistance upon high-fat diet and failure to
remodel adipose tissue upon withdrawal of this diet (Jonker
et al., 2012). While response to TZDs has not been reported in
FGF1 null mice, pharmacological administration of FGF1 was
recently shown to be insulin sensitizing in mice (Suh et al., 2014).
TZDs are potent synthetic PPARg ligands, but the endoge-
nous ligand remains uncertain despite a number of candidates
(e.g., certain unsaturated fatty acids, prostaglandins, oxidized
lipids, and serotonin metabolites) which generally have much
lower affinity for PPARg and uncertain physiological relevance
(Schupp and Lazar, 2010). Assuming that endogenous com-
pounds do modulate PPARg activity, it is also unknown whether
TZDs have potent effects because they are simply stronger
agonists or, alternatively, that TZDs have actions that are quali-
tatively different than those of the endogenous regulators.
What Tissue(s) Is Most Important for TZD Function?
Over the past 15 years, manymousemodels have been reported
that elucidate the tissue-specific effects of PPARg and TZDs
(Table 2). PPARg is by far most abundant in adipose tissue,
and adipose tissue is necessary for insulin-sensitizing effects
of TZDs (Chao et al., 2000). Furthermore, PPARg gain of function
in adipose tissue is sufficient to cause whole-body insulin sensi-
tization (Sugii et al., 2009). A study of mice with deletion of
PPARg in fat demonstrated loss of some but not all TZD effects,
although these mice had a surprisingly mild lipodystrophic
phenotype (He et al., 2003). This differs from amore recent dele-
tion model which described severe lipoatrophic diabetes,
though TZD effects were not examined in this case (Wang
et al., 2013).
PPARg deletion in liver and muscle also causes insulin resis-
tance, though to a much lesser degree than deletion in fat, and
with variable effects in response to TZDs. Two groups havedeleted PPARg selectively in skeletal muscle, with one reporting
resistance to insulin sensitization by TZDs (Hevener et al., 2003),
yet the other showing normal response to TZDs (Norris et al.,
2003). The reasons for this discrepancy remain unclear. Mice
lacking PPARg in liver respond to TZDs normally unless adipose
tissue is also defective (Gavrilova et al., 2003). PPARg and TZDs
have also been implicated in pancreatic b cells. While TZDs
enhance insulin secretion from isolated islets in a PPARg-depen-
dent manner, mice lacking islet PPARg have normal glucose
homeostasis and response to TZDs (Rosen et al., 2003).
In addition to the classic metabolic tissues (fat, liver, muscle,
and endocrine pancreas), metabolic phenotypes have also
been found in mice lacking PPARg in immune cells, particularly
those cells resident in adipose tissue and altered in obesity.
PPARg is expressed in macrophages and affects their pheno-
type, as PPARg (Odegaard et al., 2007) and TZDs (Bouhlel
et al., 2007) lead to alternative M2 polarization, as opposed to
classic proinflammatory M1 polarization. Rather than a direct
effect on macrophages, one study proposes that TZDs affect
adipose resident macrophage polarization indirectly by lipid
partitioning (Prieur et al., 2011), similar to ‘‘lipid steal’’ between
tissues. Nonetheless, mice lacking macrophage PPARg show
whole-body insulin resistance, though this is still improved by
rosiglitazone (Hevener et al., 2007).
More recently, it was reported that a subset of regulatory T
(Treg) cells express high levels of PPARg and accumulate in
visceral fat of lean mice, but they decrease in diet-induced
obesity and increase 4-fold upon pioglitazone treatment.
Remarkably, diet-induced obese mice with PPARg ablation in
Treg cells showed no improvement in glucose tolerance or mea-
sures of insulin sensitivity in response to pioglitazone (Cipolletta
et al., 2012), though the effects were small in the control group.
Beyondmacrophages and Treg cells, PPARg and TZDs have also
been proposed to have effects in other immune cells like den-
dritic cells (Szatmari et al., 2006). It should be noted that while in-
hibition of atherosclerosis by TZDs inmousemodels may involve
their anti-inflammatory effects in macrophages (Li et al., 2000),
the ability of pioglitazone to decrease atherosclerotic lesions is
lost in mice lacking PPARg in smooth muscle cells (Chang
et al., 2012; Hamblin et al., 2011).
Two recent rodent studies support a role for PPARg and TZDs
in the central nervous system (Lu et al., 2011; Ryan et al., 2011).
Both showed that rosiglitazone increases food intake and
weight gain, and this was also seen with administration at low
doses into the third cerebral ventricle to avoid systemic effects
(Ryan et al., 2011). The hyperphagic effects of oral rosiglitazone
were lost upon blocking brain PPARg activity (in mice by
neuron-specific PPARg knockout or in rats by CNS treatment
with a PPARg antagonist or siRNA). Furthermore, excess brain
PPARg activity resulted in weight gain, while attenuation of brain
PPARg activity reduced weight gain on a high-fat diet. Rosiglita-
zone still improved whole-body (but not hepatic) insulin sensi-
tivity in mice lacking PPARg in the brain (Lu et al., 2011),
indicating that CNS effects may account for some but not all
the metabolic effects of TZDs. PPARg mRNA and immunoreac-
tive protein can be detected in certain brain regions (Sarruf
et al., 2009), but it remains uncertain whether functional levels
of PPARg protein are present in neurons, and if so which genes
are TZD regulated.Cell Metabolism 20, October 7, 2014 ª2014 Elsevier Inc. 581
Table 2. Tissue-Specific Effects of TZDs and PPARg in Mouse Models
Tissue TZD Effect in Tissue or Cell Type
Tissue-Specific PPARg Knockout
NoteOverall Effect TZD Effect
White adipose Increased adipogenesis
Increased lipid storage
Increased browning
Increased insulin sensitivity
Severe lipoatrophy with marked insulin
resistance (Wang et al., 2013)
Not tested, but absent in another
model of lipoatrophy (Chao et al.,
2000)
In another knockout model with milder
lipodystrophy, the TZD effect was
diminished but not lost (He et al., 2003)
Liver Decreased hepatic steatosis
Increased insulin sensitivity
Excess adiposity and whole-body insulin
resistance (Gavrilova et al., 2003)
Normal response Less steatosis is likely via ‘‘lipid steal’’ to
adipose, as TZD effect on isolated
hepatocytes is lipogenic
Skeletal muscle Increased insulin sensitivity
Decreased ectopic lipids (likely indirect
effects via ‘‘lipid steal’’ to adipose)
Excess adiposity and whole-body insulin
resistance (Norris et al., 2003)
Normal response Another knockout model had conflicting
results, with no response to TZDs (Hevener
et al., 2003)
Pancreatic b cells Increased insulin secretion Altered islet mass but normal glucose
homeostasis (Rosen et al., 2003)
Normal response Improved beta cell function on TZDs is also
due to lower glucose and less insulin
demand
Macrophage Less M1 pro-inflammatory polarization
More M2 polarization
Whole-body insulin resistance (Hevener
et al., 2007)
Partial response Macrophages reside in adipose tissue as
well as atherosclerotic lesions
Regulatory T cell
(Treg)
Increased number of Treg cells in obese
visceral fat
Decreased adipose Treg (Cippolletta et al.,
2012)
No longer significant response Effects of TZDs on isolated Treg cells have
not yet been reported
Brain Increased food intake Less weight gain on high-fat diet (Lu et al.,
2011)
Normal but no longer increase
food intake
In brain knockout mice, TZDs restored
whole-body but not hepatic insulin
sensitivity
Kidney Fluid retention No whole-body effect reported (Guan et al.,
2005)
No longer retain fluid Same result in a different knockout model
(Zhang et al., 2005)
Bone Increased osteoblasts
Decreased osteoclasts
Increased adipocytes
Not known Not known FGF21 deletion eliminates TZDs effects on
bone (Wei et al., 2012)
Cardiac muscle Cardiac hypertrophy (mice)
Increased lipid storage
Hypertrophy with normal cardiac function
(Duan et al., 2005)
Still induce further cardiac
hypertrophy
There is evidence for PPARg-independent
effects of TZDs on cardiomyocytes
Vascular smooth
muscle
Reduced atherosclerotic lesions (may also
be due to effects on macrophages or
endothelial cells)
Perivascular adipose tissue lost (Chang
et al., 2012)
No longer reduces atheromas
(Hamblin et al., 2011)
Both rosiglitazone and pioglitazone protect
against atherosclerosis in mouse models
While PPARg and TZD effects in adipose tissue are best validated, they have been investigated in other tissues and cell types. Many TZD effects are reported in isolated cells or in tissues of a whole
organism, and gene-targeted ‘‘knockout’’ mice have been generated and studied that lack PPARg in various tissues.
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ReviewTaken together, it is remarkable that the insulin-sensitizing
effects of TZDs dissipate not only when PPARg is removed in
adipose tissue but also in several different nonadipose tissues.
The evidence for adipose tissue is very robust, validated in mul-
tiple independent studies with complementary lines of evidence.
The effects in other tissues, however, are typically quite small
and based on one or two studies, without independent valida-
tion. Future studies are necessary to determine conclusively
which of these effects are most important, which are additive,
and whether they are coordinated in the context of the whole
organism.
Targeting PPARg through Posttranslational
Modifications
The now-classic model of nuclear receptor function posits that
ligand binding causes a conformational change, resulting in
release of corepressors and recruitment of coactivators, thus
transcriptional activation of target genes (Lehrke and Lazar,
2005). Ligands are thus often defined by ‘‘classical agonism’’
in in vitro assays of transcriptional activation or nuclear receptor
association with coregulatory peptides (for example, Hughes
et al., 2014). However, challenges to this model have emerged,
as TZDs have other effects on PPARg, including posttransla-
tional modifications.
The two best-studied phosphorylation sites on PPARg are
Ser112 and Ser273 (numbering is for the PPARg2 isoform). Other
phosphorylation sites have been proposed (Ser46 and Ser51)
which may affect PPARg subcellular localization (von Knethen
et al., 2010), but these have not been studied to the same extent.
Phosphorylation of PPARg at Ser112 is inhibitory, decreasing
affinity for TZDs (Hu et al., 1996; Shao et al., 1998). In mice, mu-
tation of Ser112 to Ala mimicked the effect of TZDs, with pre-
served insulin sensitivity on high-fat diet despite similar weight
gain to controls (Rangwala et al., 2003). Ser112 phosphorylation
is thought to occur via growth-factor stimulatedMAP kinases like
MEK1, and several phosphatases have been proposed, most
recently PPM1B (Tasdelen et al., 2013). Paradoxically, it has
also been reported that phosphorylation of Ser112 by the kinase
Cdk9 stimulates rather than represses PPARg activity (Iankova
et al., 2006). Notably, no reports have indicated that TZDs affect
Ser112 phosphorylation. In contrast, the more recently discov-
ered phosphorylation at Ser273 by Cdk5 is blocked by TZDs
(Choi et al., 2010). Interestingly, mutation of Ser273 to Ala did
not affect overall activity of PPARg but led to selective activation
of a subset of PPARg target genes including adiponectin, sug-
gesting that phosphorylation normally suppresses expression
of these beneficial genes—and that TZDs activate them. Further-
more, even partial agonists with weak classical agonism of
PPARg (like MRL-24) could inhibit Ser273 phosphorylation,
similar to full agonists like rosiglitazone. This has led to the
hope that drugs decreasing Ser273 phosphorylation of PPARg
with minimal agonist activity might confer the benefits of TZDs
without the adverse events. Indeed, two compounds called
SR1664 (Choi et al., 2011) and GQ-16 (Amato et al., 2012) are re-
ported to confer equal insulin sensitization to rosiglitazone in
mice, yet remarkably without weight gain or edema. Similarly,
natural legume-derived compounds called amorfrutins are also
weak PPARg ligands that inhibit Ser273 phosphorylation and
have surprisingly potent insulin-sensitizing effects (Weidneret al., 2012). Ser273 phosphorylation was also reduced in mice
with adipose tissue deletion of the corepressor NCoR, another
model in which increased PPARg activity mimics TZD treatment
(Li et al., 2011).
PPARg can also be covalently attached to ubiquitin or small
ubiquitin-like modifier (SUMO) proteins. Like the nearby Ser112
phosphorylation, SUMOlyation of PPARg at Lys107 also re-
presses its transcriptional activity (Floyd and Stephens, 2004;
Ohshima et al., 2004; Yamashita et al., 2004), and TZDs are
not reported to affect this. In contrast, TZDs are reported to
induce SUMOlyation at Lys395, which is central to the ‘‘transre-
pression’’ model whereby PPARg in macrophages stabilizes
corepressors at inflammatory gene promoters (Pascual et al.,
2005). TZDs also cause the ubiquitination and degradation of
PPARg (Hauser et al., 2000), and the ubiquitin ligase Siah2
has been implicated (Kilroy et al., 2012). Ubiquitination occurs
in the ligand binding domain, though the exact site is
unknown. While proteasomal degradation of PPARg would
clearly decrease transcriptional activation, there is also evidence
that PPARg ubiquitination is necessary for its activity (Kilroy
et al., 2009).
Most recently, glycosylation and acetylation of PPARg have
been reported. Glycosylation of PPARg (O-GlcNAc at Thr84)
was shown in cultured mouse adipocytes, and this decreased
basal and TZD-stimulated reporter activity (Ji et al., 2012),
though it was not reported whether TZDs affected glycosylation.
Rosiglitazone was shown to decrease acetylation of overex-
pressed PPARg at Lys268 and Lys293, while other acetylation
sites (Lys98, Lys107, and Lys218) were not affected by TZD
(Qiang et al., 2012). These authors propose a model whereby
ligand-mediated PPARg interaction with the deacetylase SirT1
results in deacetylation and alterations in the PPARg gene acti-
vation profile favoring a beige adipocyte phenotype. Another
recent study suggests a conflicting model based on an observa-
tion that pioglitazone instead increases acetylation of endoge-
nous PPARg in cultured adipocytes (Jiang et al., 2014).
Given that manymodifications of PPARg are in close proximity
based on its crystal structure, there are potential interactions
among these phosphorylated, SUMOlyated, ubiquitinated, gly-
cosylated, and acetylated residues. However, it must be noted
most studies of PPARg posttranslational modifications have
been performed in cells with limited independent validation.
Only Ser112 has been shown to affect insulin sensitivity in a
whole-animal model (Rangwala et al., 2003). While other
modifications are potentially attractive targets for new drug
development, enthusiasm should be tempered until there is
rigorous in vivo validation of their relevance in physiology and
disease.
Non-PPARg Targets of TZDs?
TZDs have rapid nontranscriptional effects that appear to be in-
dependent of PPARg. One such effect is activation of AMP-
kinase (LeBrasseur et al., 2006), which would be predicted to
have insulin-sensitizing effects (Hardie, 2014). TZDs have also
been reported to bind mitochondrial membranes (Feinstein
et al., 2005), and the pyruvate carriers MCP1 and MCP2 have
recently been strongly implicated as the mitochondrial targets
of TZDs (mTOTs) (Colca et al., 2013a; Divakaruni et al., 2013).
MSDC-0160 (aka PNU-91325) is considered the prototypeCell Metabolism 20, October 7, 2014 ª2014 Elsevier Inc. 583
Cell Metabolism
ReviewmTOT modulator, and though it is described as ‘‘PPARg-
sparing,’’ it is important to note that it is a TZD which still acti-
vates PPARg in reporter assays, though 20-fold less potently
than pioglitazone (Bolten et al., 2007). A phase 2 randomized
clinical trial of MSDC-0160 was recently reported, and doses
of 100–150 mg gave similar HbA1c lowering as 45 mg of piogli-
tazone at 12 weeks (Colca et al., 2013b). Notably, however, the
typical signs of PPARg agonism were still present at these
doses: there was significant fluid retention (based on hemoglo-
bin decrease), weight gain, and elevations in adiponectin
compared to placebo, though each was only 50% as much
as pioglitazone. MSDC-0160 is currently being developed for
neurodegenerative conditions rather than T2DM, but the similar
drug MSDC-0602 was an effective insulin sensitizer in rodents
(Chen et al., 2012) and in an unpublished phase 2 trial for
diabetes (NCT01280695). Given that both compounds are piogli-
tazone derivatives with some PPARg activation (Figure 2), a
better test of mTOT as a drug target would require a non-TZD
mTOT inhibitor completely devoid of PPARg agonism.
It has even been suggested that beneficial effects of TZDs on
insulin sensitivity stem primarily from themitochondrial pathway,
while PPARg mediates undesired effects (Colca et al., 2013b).
However, PPARg is clearly implicated in insulin sensitivity by
strong and unbiased evidence from human genetics. Rare fam-
ilies with mutations in the ligand binding domain of PPARg show
autosomal dominant inheritance of a syndrome of lipodystrophy
and insulin resistance (Barroso et al., 1999). Furthermore, com-
mon polymorphisms in the PPARG gene locus are associated
with risk of type 2 diabetes in genome-wide association studies
(Gouda et al., 2010). The causative risk allele was long thought to
be a coding Pro12Ala polymorphism in PPARg2; however, a
recent study has indicated that the true causal polymorphism
lies upstream of PPARg2 and affects its gene regulation (Clauss-
nitzer et al., 2014). Regardless, PPARg is clearly associated with
insulin sensitivity and diabetes, so it would be very surprising if
PPARg agonism was only incidental to the antidiabetic effects
of its potent TZD ligands. Another strong argument favoring
PPARg as the target of the insulin sensitizing effects of TZDs is
the observation that several PPARg agonists lack the TZD struc-
ture, and thus presumably the non-PPARg effects of TZDs, yet
are potent insulin sensitizers (Figure 2, see below).
More New Drug Development: Selective, Partial, and
Dual Agonists
There has long been hope that, analogous to selective estrogen
receptor modifiers (SERMs), selective PPARg modulators
(SPARMs, either TZD or non-TZD) with reduced or partial agonist
activity may retain glucose-lowering benefits with decreased risk
of adverse effects (Rangwala and Lazar, 2002). Such drugs that
affect mTOTs or PPARg Ser273 phosphorylation are described
above. The TZD balaglitazone has partial agonist activity with
fewer side effects in rat models (Henriksen et al., 2009), and a hu-
man trial showed similar glycemic efficacy to pioglitazone with
trends toward fewer sides effects (Henriksen et al., 2011). How-
ever, in this trial, balaglitazone at 10 or 20mg clearly caused fluid
retention, edema, and increased body fat compared to placebo,
and only the lower dose—which was less effective at lowering
glucose—showed differences in these side effects compared
to 45 mg pioglitazone. Bone loss was not significant in any584 Cell Metabolism 20, October 7, 2014 ª2014 Elsevier Inc.group, though a trend toward decrease was present for pioglita-
zone. The diarylsulfonamide non-TZD class of PPARg partial
agonists, which includes the drug INT-131, is structurally distinct
from TZDs with different binding properties (Bajare et al., 2012).
In mousemodels, INT-131 failed to cause volume expansion and
actually increased bone density, and a recent 24-week trial of
362 patients with T2DM showed equal glucose lowering efficacy
to 45 mg pioglitazone with evidence for less fluid retention
(DePaoli et al., 2014). MBX-102 and GW1929 are two other
structurally distinct non-TZD agonists with promising results in
animal and cell models (Brown et al., 1999; Gregoire et al.,
2009). However, despite this promise, further development of
SSPARMs appears to have mostly halted.
Dual agonists of PPARg and the related nuclear receptor
PPARa also hold promise for treating insulin resistance and dys-
lipidemia in metabolic syndrome, as they may combine the
beneficial effects of TZDs and fibrates (hypolipidemic PPARa
agonists) with fewer side effects. The dual agonist saroglitazar
is approved in India, and a phase 3 study of 302 patients with dia-
betic dyslipidemia despite statin therapy showed that addition of
saroglitazar improved triglycerides and fasting glucose (Jani
et al., 2014). AleCardio was a large international multicenter
phase 3 trial of 7,226 patients with T2DM hospitalized for acute
cononary syndrome, randomized to the dual agonist aleglitazar
versus placebo (Lincoff et al., 2014). While aleglitazar had the
expected effects on glycemia and lipoproteins, the trial was
stopped early at a median of 2 years due to futility, as the primary
endpoint of recurrent heart attack, stroke, or cardiovascular
death was not altered, yet there was evidence for increased
serious adverse events. Smaller trials of other dual agonists
(aleglitazar and tesaglitazar) have also been unsuccessful. The
failure of the large AleCardio RCT may spell the end of drug
development for dual PPAR agonists, and unfortunately even
dampens enthusiasm for developing new drugs that target
PPARg.
Why Does It Matter? The Case for Reducing Insulin
Levels
Diabetes continues to increase in prevalence, affecting 29million
people in theUnited States (9.3%) in 2012, up 3million from 2010
(CDC, 2014). Insulin resistance is the sine qua non of T2DM, and
hence only therapies that improve insulin sensitivity address
the basic pathophysiology of this condition (DeFronzo, 2004).
Furthermore, there is a school of thought that the increased con-
centrations of insulin that are prevalent in T2DM are a major
contributor to the comorbidities, particularly macrovascular dis-
ease (Despre´s et al., 1996). This would explain why even insulin-
resistant patients without diabetes are prone to the same
vascular complications (Facchini et al., 2001), and thus it is of
great concern that one-third of Americans (86 million) have
prediabetes (CDC, 2014). Reaven has suggested that hyperin-
sulinemia is an etiologic component of other dysmetabolic
parameters associated withmetabolic syndrome and cardiovas-
cular risk, including hypertension, low HDL, and hypertriglyceri-
demia (Reaven, 1988). Even further, while hyperinsulinemia
certainly results from obesity and insulin resistance, Ludwig
and Friedman have promoted the model whereby insulin posi-
tively feeds back to cause overeating and adiposity in a vicious
cycle (Ludwig and Friedman, 2014). Indeed, a mouse model
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tance to diet-induced hyperinsulinemia and weight gain (Mehran
et al., 2012).
Even beyond cardiometabolic disease, hyperinsulinemia is
also thought to be central to the elevated cancer risk associated
with diabetes and obesity (Gallagher and LeRoith, 2013). How-
ever, many therapies for T2DM focus on overcoming insulin
resistance by increasing insulin levels, either by stimulating
secretion of endogenous insulin (e.g., glucagon-like peptide 1
[GLP-1] receptor agonists, DPP4 inhibitors, sulfonylureas) or
by providing insulin exogenously. A very recent retrospective
cohort study of VA patients (Roumie et al., 2014) supports the
idea that high insulin levels are harmful. In patients with diabetes
started on metformin from 2001 to 2008, those for whom insulin
was added as the second agent had a significant 44% higher all-
cause mortality (mainly due to cancer) versus those adding a
sulfonylurea. Note that patients receiving any other antidiabetic
medications, including TZDs, were excluded from the study,
and thus the likely effect of TZDs to reduce insulin requirements
was not evaluated. Another very recent industry-funded retro-
spective cohort study did compare TZD to insulin and found
that patients started on pioglitazone from 2000 to 2010 had a
remarkably significant 67% lower all-cause mortality than those
started on insulin (Yang et al., 2014), though this study was
unable to adjust for glycemic control.
Since hyperinsulinemia is a plausible contributor to the comor-
bidities of type 2 diabetes, it is prudent to develop novel thera-
pies that address this underlying problem. Treatment of obesity
could address this, and while bariatric surgery is effective, clin-
ical experience with lifestyle medication and pharmacotherapy
for obesity has been disappointing to date, particularly in terms
of weight regain (Hainer et al., 2008). Novel therapeutics directed
at activating brown or beige adipocytes have promise for treating
obesity as well as diabetes, but none are currently available for
clinical use. Since TZDs are the most potent known insulin sen-
sitizers, by definition patients on TZDs will require lower levels of
endogenous and exogenous insulin to maintain euglycemia.
Indeed, patients using insulin who are started on TZDs typically
reduce their insulin dose or even discontinue insulin injections
(Yau et al., 2013). Therefore, understanding how TZDs work
and effectively harnessing the underlying mechanisms with
fewer side effects would be a welcome advance in the arsenal
of antidiabetic drugs (Kahn and McGraw, 2010).
There is great hope that recent studies highlighted here may
translate to newdrug development. There is promise of selective,
partial, and dual agonism, as well as specifically targeting post-
translational modifications of PPARg. In addition to the canonical
PPARg ligand binding domain, recent studies have identified an
alternate site is occupied potently by several non-TZD ligands
but not TZDs, adding additional complexity to agonist pharma-
cology (Hughes et al., 2014). Furthermore, rather than PPARg
per se, novel drugs may also achieve insulin sensitization by tar-
geting other TZD-related systems such as AMP kinase, mito-
chondrial transporters, or FGFs. Tissue selectivity is also a key
issue. For instance, a PPARg agonist that failed to reach the
brain, kidneys, or skeleton might be expected to eliminate side
effects ofweight gain, fluid retention, andbone loss, respectively.
The futuremay involve targeting small molecule drugs to relevant
tissues—such as TZDs to adipose tissue—by conjugation withselective peptides, as estrogen has been conjugated to GLP-1
to target tissues that express the GLP-1 receptor and treat meta-
bolic syndrome in mice (Finan et al., 2012). Another way to
achieve tissue selectivity might be an orally administered PPARg
agonist that is inactivated by first-pass liver metabolism, thus
having selective effects on visceral fat without reaching other tis-
sues. Targeting of TZDs selectively to immune cells, both in adi-
pose tissue and the vascular wall, may likewise be beneficial.
Another way forward would be to identify those patients most
likely to benefit from TZDs or novel insulin sensitizers with mini-
mal risks. It has been noted that about a quarter of patients with
T2DM are ‘‘nonresponders’’ who do not improve insulin sensi-
tivity on TZDs, while an equal number have large responses
(Sears et al., 2009). The umbrella of T2DM encompasses many
heterogeneous phenotypes (Gale, 2013), and further investiga-
tion may identify a distinct subset of patients in which TZDs
may be most effective. Genetic predispositions, such as poly-
morphisms affecting PPARg genomic occupancy, may also
modulate response to the insulin-sensitizing or harmful effects
of TZDs. Together, new drug development and more personal-
ized pharmacotherapy may fulfill the promise of insulin sensitiza-
tion in T2DM.
Conclusions
Despite the benefits of insulin sensitization by TZDs, this once
widely used class of drugs has fallen into disrepute and disuse.
The goal of diabetes therapy is not only glucose lowering, but
also protection from its comorbidities, and in this aspect, TZDs
carry benefits and risks that must be weighed, as for any phar-
macological treatment. In the case of TZDs, public attention
has been focused more on the potential harms of these drugs
than on their benefits. For instance, the meta-analysis showing
cardiovascular risk for rosiglitazone had drastic effects on policy
and prescribing, while other meta-analyses showing beneficial
effects—like cancer protection by TZDs—are largely dismissed.
Even randomized studies consistently indicating cardiovascular
benefits of pioglitazone are dismissed for various reasons (i.e.,
PROactive did not meet the primary endpoint, PERISCOPE
looked at a surrogate endpoint, etc.). Bladder cancer risk based
on observational studies is nowwidely cited as a reason to aban-
don pioglitazone, yet the absolute risk increase is extremely
small, and fracture risk—with better clinical and mechanistic
evidence and likely greater harm—is a more convincing reason
to reconsider this drug.
The data may warrant a more balanced view weighing the
potential risks and benefits for TZDs, particularly pioglitazone,
which might be used more often in selected patients. For
instance, there may be a role in younger patients with prediabe-
tes or early T2DM, when insulin sensitization may do the most to
reduce hyperinsulinemia and preserve b cell function—but frac-
ture risk is much less than in the elderly. This is consistent with
the current evidence-based trend to individualize T2DM man-
agement, as early glycemic control may have long-term cardio-
vascular benefits via ‘‘metabolic memory,’’ yet tight glycemic
control in older patients with long-standing diabetes does not
carry these benefits and may even cause harm (American Dia-
betes Association, 2014).
Whatever the balance between benefits and risks of current
TZD therapies, the promise of insulin sensitization for treatmentCell Metabolism 20, October 7, 2014 ª2014 Elsevier Inc. 585
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Reviewof metabolic syndrome and diabetes should not be abandoned.
Basic mechanistic studies continue to unravel the complex
biology underlying the beneficial and adverse effects of TZDs,
and better understanding of their salient as well as their harmful
effects has great potential to pave the way for the next genera-
tion of therapeutics.
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